Qlucore, listed on Nasdaq First North, can now release a new version of Qlucore Insights specifically designed for the lung cancer field, with the capability to classify primary lung samples as well as metastatic lesions.
The lung cancer model is being developed with Heidelberg University Hospital, supported by a Eurostars Joint European Programme grant.
The new Qlucore Insights model provides a comprehensive overview of the lesion that is being analyzed. The model assigns a sample to one of 18 subgroups, where the subgroups include the major primary lung cancer subtypes, twelve subgroups for metastatic cancer such as breast, colorectal, or kidney cell cancer and two subtypes for infections/inflammatory conditions, i.e. Sarcoidosis and TBC.
The Qlucore Insights lung cancer model is based on RNA data from more than 300 carefully selected samples (FFPE). The model is developed using modern and tailored AI-based machine learning techniques. Gene fusions are also detected and reported. Data processing and results are easy and fast to generate with the foundation in standard RNA-seq kits, standard workflows and NGS-instruments.
